Cargando…

Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes

BACKGROUND/AIMS: To assess visual acuity (VA) outcomes and antivascular endothelial growth factor (anti-VEGF) therapy intensity in retinal vein occlusion (RVO)-related macular oedema (ME). METHODS: A retrospective study was completed in treatment-naïve patients with RVO-related ME from 2013 to 2019,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciulla, Thomas, Pollack, John S, Williams, David F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639936/ https://www.ncbi.nlm.nih.gov/pubmed/33055088 http://dx.doi.org/10.1136/bjophthalmol-2020-317337

Ejemplares similares

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
por: Ciulla, Thomas A, et al.
Publicado: (2021)

Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result
por: Lip, P L, et al.
Publicado: (2018)

Macular dynamics and visual acuity prognosis in retinal vein occlusions - ways to connect
por: Dărăbuș, Diana-Maria, et al.
Publicado: (2023)

The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy
por: Nicholson, Luke, et al.
Publicado: (2021)

Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Treatment of macular edema due to retinal vein occlusions
por: Channa, Roomasa, et al.
Publicado: (2011)

Vitrectomy for macular edema due to retinal vein occlusion
por: Kumagai, Kazuyuki, et al.
Publicado: (2019)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Importance of Central Retinal Sensitivity for Prediction of Visual Acuity after Intravitreal Bevacizumb in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion
por: Sugimoto, Masahiko, et al.
Publicado: (2016)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
por: Bertelmann, Thomas, et al.
Publicado: (2017)

Patient's Self-recognition of Reduced Visual Acuity Due to Recurrence of Macular Edema and Prompt Visitation to the Hospital in Retinal Vein Occlusion
por: Jeong, Seong Hun, et al.
Publicado: (2014)

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study
por: Arai, Yusuke, et al.
Publicado: (2023)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
por: Horner, Faye, et al.
Publicado: (2020)

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review
por: Glanville, Julie, et al.
Publicado: (2014)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
por: Hunter, Alexandra, et al.
Publicado: (2022)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
por: Eltutar, Kadir, et al.
Publicado: (2013)

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure
por: Liu, Haiyang, et al.
Publicado: (2018)

Foveal Eversion is Associated with High Persistence of Macular Edema and Visual Acuity Deterioration in Retinal Vein Occlusion
por: Arrigo, Alessandro, et al.
Publicado: (2023)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion
por: Pidro, Ajla, et al.
Publicado: (2022)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

Retinal Vascular Resistance Significantly Correlates With Visual Acuity After 1 Year of Anti-VEGF Therapy in Central Retinal Vein Occlusion
por: Matsumoto, Makiko, et al.
Publicado: (2021)

The Caliber of Optociliary Shunt Vessels Is Associated with Macular Blood Flow and Visual Acuity in Central Retinal Vein Occlusion
por: Kanai, Masanori, et al.
Publicado: (2021)

Baseline Predictors of Visual Acuity and Retinal Thickness in Patients with Retinal Vein Occlusion
por: Kim, Sang Jin, et al.
Publicado: (2015)

The role of serum metrics in anti- VEGF treatment for macular edema induced by retinal vein occlusion
por: Wang, Yun-Chang, et al.
Publicado: (2023)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gdp6n3i515glpu4dlc33apvvlq